BioPharmSignal logoBioPharmSignal

Biotech News

Acrivon to Highlight the Power of its AP3 Platform for Streamlined, Pathway-Based Drug Discovery and Development with Oral and Poster Presentations at AACR D3 Conference

Acrivon Therapeutics (ACRV)Acrivon TherapeuticsConference / presentation

Presentations feature mechanistic data on ACR-2316, a potential first-in-class, clinical WEE1/PKMYT1 inhibitor, rationally designed with AP3 for potent single agent activity and superior therapeutic index Early clinical responses, including partial responses (PRs) across multiple AP3-predicted

Related news

REPLReplimune Group2026-05-31 12:00 EST

Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

ACRVAcrivon Therapeutics2026-08-05 12:30 EST

Acrivon Advances ACR-2316, a Potential First-in-Class WEE1/PKMYT1 Inhibitor, into Randomized Dose Expansion in its Ongoing Phase 1/2 Study

CMPXCompass Therapeutics2026-07-17 14:42 EST

Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026

COGTCogent Biosciences2026-06-12 12:01 EST

Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress

ZNTLZentalis2026-07-17 20:15 EST

Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026

KURAKura Oncology2026-07-14 11:02 EST

Kura Oncology to Present First Long-Term Follow-Up Data Further Supporting Darlifarnib’s Potential to Enhance VEGFR-Targeted Therapy in Renal Cell Carcinoma at KCRS 2026

RVMDRevolution Medicines2026-06-24 23:31 EST

Revolution Medicines to Present Clinical Data from RAS(ON) Inhibitor Combination Trials in Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026

LYELLyell Immunopharma2026-06-25 12:00 EST

Lyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

LYELLyell Immunopharma2026-06-01 12:00 EST

Lyell Immunopharma Announces Participation in Goldman Sachs 47th Annual Global Healthcare Conference 2026

SNDXSyndax Pharmaceuticals2026-06-02 20:01 EST

Syndax Highlights Revuforj® (revumenib) Data Presented at ASCO 2026, Including an Oral Presentation of Post-Transplant Data

View all latest news

Acrivon Therapeutics

Generative Phosphoproteomics Platform Acrivon Therapeutics uses its AP3 platform to measure drug-regulated signaling inside intact cells and identify tumors most likely to respond to specific medicines. ACR-368 ACR-368 is a CHK1/2 inhibitor in a registrational-intent Phase 2b study, with increasing focus on serous endometrial cancer and...

Recent company news

ACRVAcrivon Therapeutics2026-08-05 12:30 EST

Acrivon Advances ACR-2316, a Potential First-in-Class WEE1/PKMYT1 Inhibitor, into Randomized Dose Expansion in its Ongoing Phase 1/2 Study

ACRVAcrivon Therapeutics2026-07-21 20:30 EST

Acrivon to Highlight the Power of its AP3 Platform for Streamlined, Pathway-Based Drug Discovery and Development with Oral and Poster Presentations at AACR D3 Conference

ACRVAcrivon Therapeutics2026-05-21 11:30 EST

Acrivon Therapeutics to Present at TD Cowen’s 7th Annual Oncology Innovation Summit

ACRVAcrivon Therapeutics2026-05-15 20:00 EST

Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

ACRVAcrivon Therapeutics2026-05-13 20:10 EST

Acrivon Reports First Quarter 2026 Financial Results and Highlights Progress Towards Key 2026 Clinical Catalysts

Stock data

Close
1.69 USD
Market cap
67.2M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States